 | • レポートコード：MRC2-11QY02581 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、148ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗肥満薬（抗肥満薬）のグローバル市場について調査・分析したレポートです。種類別（処方薬、OTC薬）市場規模、用途別（小児期（0-6）、少年（7-17）、青年（18-40）、中年（41-60）、高齢者（60歳以上））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗肥満薬（抗肥満薬）の競争状況、市場シェア ・世界の抗肥満薬（抗肥満薬）市場：種類別市場規模 2015年-2020年（処方薬、OTC薬） ・世界の抗肥満薬（抗肥満薬）市場：種類別市場規模予測 2021年-2026年（処方薬、OTC薬） ・世界の抗肥満薬（抗肥満薬）市場：用途別市場規模 2015年-2020年（小児期（0-6）、少年（7-17）、青年（18-40）、中年（41-60）、高齢者（60歳以上）） ・世界の抗肥満薬（抗肥満薬）市場：用途別市場規模予測 2021年-2026年（小児期（0-6）、少年（7-17）、青年（18-40）、中年（41-60）、高齢者（60歳以上）） ・北米の抗肥満薬（抗肥満薬）市場分析：米国、カナダ ・ヨーロッパの抗肥満薬（抗肥満薬）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗肥満薬（抗肥満薬）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗肥満薬（抗肥満薬）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗肥満薬（抗肥満薬）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Zafgan、Vivus、Shionogi、Sanofi、Rhythm Pharmaceuticals、Pfizer、Orexigen Therapeutics、Novo Nordisk、Norgine、Nalpropion Pharmaceuticals Inc.、Merck、GlaxoSmithKline、F.Hoffmann-La Roche、Eisai、Boehringer Ingelheim、Bayer AG、AstraZeneca、Arena Pharmaceuticals、Amylin、Alizyme ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories.
Market Analysis and Insights: Global Anti-Obesity Drugs (Anti-obesity Medication) Market
The global Anti-Obesity Drugs (Anti-obesity Medication) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-Obesity Drugs (Anti-obesity Medication) Scope and Market Size
Anti-Obesity Drugs (Anti-obesity Medication) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Obesity Drugs (Anti-obesity Medication) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Obesity Drugs (Anti-obesity Medication) market is segmented into
by Drug Varieties
Prescription Drugs
OTC Drugs
by Acting
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Segment by Application, the Anti-Obesity Drugs (Anti-obesity Medication) market is segmented into
Childhood (0-6)
Juvenile (7-17)
Youth (18-40)
Middle Aged (41-60)
Elderly (Above 60)
Regional and Country-level Analysis
The Anti-Obesity Drugs (Anti-obesity Medication) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-Obesity Drugs (Anti-obesity Medication) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-Obesity Drugs (Anti-obesity Medication) Market Share Analysis
Anti-Obesity Drugs (Anti-obesity Medication) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Obesity Drugs (Anti-obesity Medication) business, the date to enter into the Anti-Obesity Drugs (Anti-obesity Medication) market, Anti-Obesity Drugs (Anti-obesity Medication) product introduction, recent developments, etc.
The major vendors covered:
Zafgan
Vivus
Shionogi
Sanofi
Rhythm Pharmaceuticals
Pfizer
Orexigen Therapeutics
Novo Nordisk
Norgine
Nalpropion Pharmaceuticals Inc.
Merck
GlaxoSmithKline
F.Hoffmann-La Roche
Eisai
Boehringer Ingelheim
Bayer AG
AstraZeneca
Arena Pharmaceuticals
Amylin
Alizyme
1 Study Coverage
1.1 Anti-Obesity Drugs (Anti-obesity Medication) Product Introduction
1.2 Market Segments
1.3 Key Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type
1.4.2 Prescription Drugs
1.4.3 OTC Drugs
1.5 Market by Application
1.5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Application
1.5.2 Childhood (0-6)
1.5.3 Juvenile (7-17)
1.5.4 Youth (18-40)
1.5.5 Middle Aged (41-60)
1.5.6 Elderly (Above 60)
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size, Estimates and Forecasts
2.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue 2015-2026
2.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales 2015-2026
2.2 Global Anti-Obesity Drugs (Anti-obesity Medication), Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-Obesity Drugs (Anti-obesity Medication) Competitor Landscape by Players
3.1 Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers
3.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2015-2020)
3.1.2 Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers
3.2.1 Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2015-2020)
3.2.2 Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-Obesity Drugs (Anti-obesity Medication) Revenue in 2019
3.2.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-Obesity Drugs (Anti-obesity Medication) Price by Manufacturers
3.4 Anti-Obesity Drugs (Anti-obesity Medication) Manufacturing Base Distribution, Product Types
3.4.1 Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Obesity Drugs (Anti-obesity Medication) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type (2015-2020)
4.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020)
4.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2015-2020)
4.1.3 Anti-Obesity Drugs (Anti-obesity Medication) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Type (2021-2026)
4.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application (2015-2020)
5.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020)
5.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2015-2020)
5.1.3 Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2015-2020)
5.2 Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-Obesity Drugs (Anti-obesity Medication) by Country
6.1.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
6.1.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Type
6.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) by Country
7.1.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
7.1.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Type
7.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) by Region
8.1.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region
8.1.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Type
8.3 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) by Country
9.1.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
9.1.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Type
9.3 Central & South America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) by Country
10.1.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
10.1.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Type
10.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Application
11 Company Profiles
11.1 Zafgan
11.1.1 Zafgan Corporation Information
11.1.2 Zafgan Description and Business Overview
11.1.3 Zafgan Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.1.5 Zafgan Related Developments
11.2 Vivus
11.2.1 Vivus Corporation Information
11.2.2 Vivus Description and Business Overview
11.2.3 Vivus Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.2.5 Vivus Related Developments
11.3 Shionogi
11.3.1 Shionogi Corporation Information
11.3.2 Shionogi Description and Business Overview
11.3.3 Shionogi Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.3.5 Shionogi Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Description and Business Overview
11.4.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.4.5 Sanofi Related Developments
11.5 Rhythm Pharmaceuticals
11.5.1 Rhythm Pharmaceuticals Corporation Information
11.5.2 Rhythm Pharmaceuticals Description and Business Overview
11.5.3 Rhythm Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.5.5 Rhythm Pharmaceuticals Related Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Description and Business Overview
11.6.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.6.5 Pfizer Related Developments
11.7 Orexigen Therapeutics
11.7.1 Orexigen Therapeutics Corporation Information
11.7.2 Orexigen Therapeutics Description and Business Overview
11.7.3 Orexigen Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.7.5 Orexigen Therapeutics Related Developments
11.8 Novo Nordisk
11.8.1 Novo Nordisk Corporation Information
11.8.2 Novo Nordisk Description and Business Overview
11.8.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.8.5 Novo Nordisk Related Developments
11.9 Norgine
11.9.1 Norgine Corporation Information
11.9.2 Norgine Description and Business Overview
11.9.3 Norgine Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.9.5 Norgine Related Developments
11.10 Nalpropion Pharmaceuticals Inc.
11.10.1 Nalpropion Pharmaceuticals Inc. Corporation Information
11.10.2 Nalpropion Pharmaceuticals Inc. Description and Business Overview
11.10.3 Nalpropion Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.10.5 Nalpropion Pharmaceuticals Inc. Related Developments
11.1 Zafgan
11.1.1 Zafgan Corporation Information
11.1.2 Zafgan Description and Business Overview
11.1.3 Zafgan Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Products Offered
11.1.5 Zafgan Related Developments
11.12 GlaxoSmithKline
11.12.1 GlaxoSmithKline Corporation Information
11.12.2 GlaxoSmithKline Description and Business Overview
11.12.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.12.4 GlaxoSmithKline Products Offered
11.12.5 GlaxoSmithKline Related Developments
11.13 F.Hoffmann-La Roche
11.13.1 F.Hoffmann-La Roche Corporation Information
11.13.2 F.Hoffmann-La Roche Description and Business Overview
11.13.3 F.Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.13.4 F.Hoffmann-La Roche Products Offered
11.13.5 F.Hoffmann-La Roche Related Developments
11.14 Eisai
11.14.1 Eisai Corporation Information
11.14.2 Eisai Description and Business Overview
11.14.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Eisai Products Offered
11.14.5 Eisai Related Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Description and Business Overview
11.15.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Boehringer Ingelheim Products Offered
11.15.5 Boehringer Ingelheim Related Developments
11.16 Bayer AG
11.16.1 Bayer AG Corporation Information
11.16.2 Bayer AG Description and Business Overview
11.16.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Bayer AG Products Offered
11.16.5 Bayer AG Related Developments
11.17 AstraZeneca
11.17.1 AstraZeneca Corporation Information
11.17.2 AstraZeneca Description and Business Overview
11.17.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.17.4 AstraZeneca Products Offered
11.17.5 AstraZeneca Related Developments
11.18 Arena Pharmaceuticals
11.18.1 Arena Pharmaceuticals Corporation Information
11.18.2 Arena Pharmaceuticals Description and Business Overview
11.18.3 Arena Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Arena Pharmaceuticals Products Offered
11.18.5 Arena Pharmaceuticals Related Developments
11.19 Amylin
11.19.1 Amylin Corporation Information
11.19.2 Amylin Description and Business Overview
11.19.3 Amylin Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Amylin Products Offered
11.19.5 Amylin Related Developments
11.20 Alizyme
11.20.1 Alizyme Corporation Information
11.20.2 Alizyme Description and Business Overview
11.20.3 Alizyme Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Alizyme Products Offered
11.20.5 Alizyme Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-Obesity Drugs (Anti-obesity Medication) Market Estimates and Projections by Region
12.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Regions 2021-2026
12.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast (2021-2026)
12.2.1 North America: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast (2021-2026)
12.2.2 North America: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast (2021-2026)
12.2.3 North America: Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast (2021-2026)
12.3.2 Europe: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-Obesity Drugs (Anti-obesity Medication) Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Obesity Drugs (Anti-obesity Medication) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anti-Obesity Drugs (Anti-obesity Medication) Market Segments
Table 2. Ranking of Global Top Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Prescription Drugs
Table 5. Major Manufacturers of OTC Drugs
Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Application 2020-2026 (K Units)
Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Regions 2015-2020 (K Units)
Table 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Regions (2015-2020)
Table 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2015-2020) (K Units)
Table 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Manufacturers (2015-2020)
Table 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Anti-Obesity Drugs (Anti-obesity Medication) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Drugs (Anti-obesity Medication) as of 2019)
Table 15. Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Price (2015-2020) (USD/Unit)
Table 18. Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Product Type
Table 20. Date of International Manufacturers Enter into Anti-Obesity Drugs (Anti-obesity Medication) Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Type (2015-2020)
Table 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Type (2015-2020)
Table 26. Anti-Obesity Drugs (Anti-obesity Medication) Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 27. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 28. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Application (2015-2020)
Table 29. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2015-2020) (K Units)
Table 30. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2015-2020)
Table 31. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2015-2020)
Table 33. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 34. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Table 35. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 36. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Table 37. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2015-2020) (K Units)
Table 38. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2015-2020)
Table 39. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2015-2020)
Table 41. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 42. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Table 43. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 44. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2015-2020) (K Units)
Table 46. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 50. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 52. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Table 53. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2015-2020) (K Units)
Table 54. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2015-2020)
Table 57. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 58. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Table 59. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 60. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2015-2020) (K Units)
Table 62. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2015-2020) (K Units)
Table 66. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2015-2020) (K Units)
Table 68. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Table 69. Zafgan Corporation Information
Table 70. Zafgan Description and Major Businesses
Table 71. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 72. Zafgan Product
Table 73. Zafgan Recent Development
Table 74. Vivus Corporation Information
Table 75. Vivus Description and Major Businesses
Table 76. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 77. Vivus Product
Table 78. Vivus Recent Development
Table 79. Shionogi Corporation Information
Table 80. Shionogi Description and Major Businesses
Table 81. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 82. Shionogi Product
Table 83. Shionogi Recent Development
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Major Businesses
Table 86. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 87. Sanofi Product
Table 88. Sanofi Recent Development
Table 89. Rhythm Pharmaceuticals Corporation Information
Table 90. Rhythm Pharmaceuticals Description and Major Businesses
Table 91. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 92. Rhythm Pharmaceuticals Product
Table 93. Rhythm Pharmaceuticals Recent Development
Table 94. Pfizer Corporation Information
Table 95. Pfizer Description and Major Businesses
Table 96. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 97. Pfizer Product
Table 98. Pfizer Recent Development
Table 99. Orexigen Therapeutics Corporation Information
Table 100. Orexigen Therapeutics Description and Major Businesses
Table 101. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 102. Orexigen Therapeutics Product
Table 103. Orexigen Therapeutics Recent Development
Table 104. Novo Nordisk Corporation Information
Table 105. Novo Nordisk Description and Major Businesses
Table 106. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 107. Novo Nordisk Product
Table 108. Novo Nordisk Recent Development
Table 109. Norgine Corporation Information
Table 110. Norgine Description and Major Businesses
Table 111. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Norgine Product
Table 113. Norgine Recent Development
Table 114. Nalpropion Pharmaceuticals Inc. Corporation Information
Table 115. Nalpropion Pharmaceuticals Inc. Description and Major Businesses
Table 116. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Nalpropion Pharmaceuticals Inc. Product
Table 118. Nalpropion Pharmaceuticals Inc. Recent Development
Table 119. Merck Corporation Information
Table 120. Merck Description and Major Businesses
Table 121. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Merck Product
Table 123. Merck Recent Development
Table 124. GlaxoSmithKline Corporation Information
Table 125. GlaxoSmithKline Description and Major Businesses
Table 126. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 127. GlaxoSmithKline Product
Table 128. GlaxoSmithKline Recent Development
Table 129. F.Hoffmann-La Roche Corporation Information
Table 130. F.Hoffmann-La Roche Description and Major Businesses
Table 131. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 132. F.Hoffmann-La Roche Product
Table 133. F.Hoffmann-La Roche Recent Development
Table 134. Eisai Corporation Information
Table 135. Eisai Description and Major Businesses
Table 136. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 137. Eisai Product
Table 138. Eisai Recent Development
Table 139. Boehringer Ingelheim Corporation Information
Table 140. Boehringer Ingelheim Description and Major Businesses
Table 141. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 142. Boehringer Ingelheim Product
Table 143. Boehringer Ingelheim Recent Development
Table 144. Bayer AG Corporation Information
Table 145. Bayer AG Description and Major Businesses
Table 146. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 147. Bayer AG Product
Table 148. Bayer AG Recent Development
Table 149. AstraZeneca Corporation Information
Table 150. AstraZeneca Description and Major Businesses
Table 151. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 152. AstraZeneca Product
Table 153. AstraZeneca Recent Development
Table 154. Arena Pharmaceuticals Corporation Information
Table 155. Arena Pharmaceuticals Description and Major Businesses
Table 156. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 157. Arena Pharmaceuticals Product
Table 158. Arena Pharmaceuticals Recent Development
Table 159. Amylin Corporation Information
Table 160. Amylin Description and Major Businesses
Table 161. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 162. Amylin Product
Table 163. Amylin Recent Development
Table 164. Alizyme Corporation Information
Table 165. Alizyme Description and Major Businesses
Table 166. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 167. Alizyme Product
Table 168. Alizyme Recent Development
Table 169. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Regions (2021-2026) (K Units)
Table 170. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Regions (2021-2026)
Table 171. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 172. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share Forecast by Regions (2021-2026)
Table 173. North America: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2021-2026) (K Units)
Table 174. North America: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 175. Europe: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2021-2026) (K Units)
Table 176. Europe: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 177. Asia Pacific: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Region (2021-2026) (K Units)
Table 178. Asia Pacific: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 179. Latin America: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2021-2026) (K Units)
Table 180. Latin America: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 181. Middle East and Africa: Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2021-2026) (K Units)
Table 182. Middle East and Africa: Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 183. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 184. Key Challenges
Table 185. Market Risks
Table 186. Main Points Interviewed from Key Anti-Obesity Drugs (Anti-obesity Medication) Players
Table 187. Anti-Obesity Drugs (Anti-obesity Medication) Customers List
Table 188. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Obesity Drugs (Anti-obesity Medication) Product Picture
Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type in 2020 & 2026
Figure 3. Prescription Drugs Product Picture
Figure 4. OTC Drugs Product Picture
Figure 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application in 2020 & 2026
Figure 6. Childhood (0-6)
Figure 7. Juvenile (7-17)
Figure 8. Youth (18-40)
Figure 9. Middle Aged (41-60)
Figure 10. Elderly (Above 60)
Figure 11. Anti-Obesity Drugs (Anti-obesity Medication) Report Years Considered
Figure 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size 2015-2026 (US$ Million)
Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales 2015-2026 (K Units)
Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2015-2020)
Figure 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region in 2019
Figure 17. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2015-2020)
Figure 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region in 2019
Figure 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Anti-Obesity Drugs (Anti-obesity Medication) Revenue in 2019
Figure 21. Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2015-2020)
Figure 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type in 2019
Figure 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2015-2020)
Figure 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type in 2019
Figure 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Price Range (2015-2020)
Figure 27. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2015-2020)
Figure 28. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application in 2019
Figure 29. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2015-2020)
Figure 30. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application in 2019
Figure 31. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country in 2019
Figure 34. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country in 2019
Figure 35. U.S. Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2019
Figure 40. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2019
Figure 41. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country in 2019
Figure 44. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country in 2019
Figure 45. Germany Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2019
Figure 56. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2019
Figure 57. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region in 2019
Figure 60. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region in 2019
Figure 61. China Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2019
Figure 84. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2019
Figure 85. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country in 2019
Figure 88. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country in 2019
Figure 89. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2019
Figure 96. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2019
Figure 97. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country in 2019
Figure 101. Turkey Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. UAE Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (2015-2020) (K Units)
Figure 106. UAE Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2019
Figure 108. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2019
Figure 109. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
抗肥満薬の世界市場（～2026年） Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain diet…- 抗肥満処方の世界市場（～2026年） Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory …
- 抗肥満療法の世界市場（～2026年） Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways. Geographically, North America captures the largest …
- 肥満管理の世界市場（～2026年） Lifestyle diseases such as diabetes and other chronic ailments are the main cause of obesity around the world. Improved healthcare and medical facilities have led to an increase in the life expectancy of people, which is the primary reason for the large geriatric population seen in the developed wor…
- 抗糖尿病治療薬の世界市場（～2026年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…